AI Article Synopsis

  • Observational studies in China have suggested that Kangbingdu oral liquid (KBD) could be effective for treating the common cold, prompting this reevaluation of its efficacy and safety.
  • A prospective randomized controlled trial involving 2647 adults aged 18 to 75 was conducted across 11 hospitals in China, comparing the effects of KBD with a placebo using various dosage levels over 5 days.
  • Results showed that the KBD group achieved a significant reduction in cold symptoms compared to the placebo group, including improvements in symptom disappearance rates and quicker normalization of body temperature.

Article Abstract

Background: Observational studies from China suggest that Kangbingdu oral liquid (KBD) may be effective in treating the common cold.

Objective: Reevaluation of efficacy and safety of Kangbingdu oral liquid after marketing and expanding population.

Design: Prospective, Pragmatic randomized controlled trial (Chictr.org.cn registration number: chiCTR-TRC-12002399). . Eleven hospitals from 3 provinces in China. Patients were recruited through 11 centers, including 7 teaching hospitals, 2 University health services, one military clinic, and one community hospital. . 2647 persons aged 18 to 75 years with Common cold. . Patients were randomly allocated to 2 groups: the treatment group Kangbingdu oral liquid (composed of 9 Chinese herbal medicines and honey) and the placebo group were divided into a standard-dose group of 10 ml every time, a middle dose group of 20 ml every time, high dose group of 30 ml every time, 3 times daily. Interventions and control were given for 5 days. . The primary outcome is the mean amount of total scores measured by the 11-primary symptoms: to observe the change of main symptoms from severe to disappear and to calculate and compare the mean amount of total scores after the periods of observation. Secondary outcomes are the disappearance rate of each symptom and the median time of body temperature returned to normal.

Results: On day 5, the Kangbingdu liquid group had significant reductions in the mean amount of total scores measured by the 11-primary symptoms (7.39 [95% CI 7.26 to 7.51] compared to the placebo group (6.43 [95%: CI 6.24 to 6.62]). The Kangbingdu liquid can improve the remission rate of accompanying symptoms on day 5 including aversion to wind, aversion to cold, fever, cough, stuffy, runny nose, sore throat, muscular aches, headache, fatigue, and sweat ( < 0.0001). Significant reductions in time of body temperature to return to normal in the Kangbingdu liquid group (P50, 48.33 [95% CI 46.00 to 52.50] compared with the control group (P50, 64.59 [95% CI 51.08 to 70.50] (=0.0022). 13 (0.7%) participants in the Kangbingdu liquid group and 1(0.2%) participants in the placebo group ( > 0.05) had treatment-related AEs, which mainly include diarrhea and dyspepsia in the Kangbingdu liquid group and constipation in the placebo group.

Conclusion: The study's conclusion in this paper was based on the placebo, Kangbingdu oral liquid two groups which clinically diagnosed the common cold and flu. (1) Kangbingdu oral liquid can effectively improve the comprehensive clinical symptoms of common adult cold, also improved main symptoms, including sore throat, muscle aches, headache, and so on. (2) Kangbingdu oral liquid effectively shortens the time of body temperature to return to normal.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458411PMC
http://dx.doi.org/10.1155/2022/9968171DOI Listing

Publication Analysis

Top Keywords

kangbingdu oral
28
oral liquid
28
kangbingdu liquid
20
liquid group
16
kangbingdu
12
liquid
12
common cold
12
group
12
placebo group
12
amount total
12

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!